A Novel Development of Sarcoidosis Following COVID-19 Vaccination and a Literature Review

Tadahisa Numakura; Koji Murakami; Tsutomu Tamada; Chiaki Yamaguchi; Chihiro Inoue; Shinya Ohkouchi; Naoki Tode; Hirohito Sano; Hiroyuki Aizawa; Kei Sato; Ayumi Mitsune; Hajime Kurosawa; Toru Nakazawa; Hisatoshi Sugiura

doi:10.2169/internalmedicine.0104-22

A Novel Development of Sarcoidosis Following COVID-19 Vaccination and a Literature Review

Tadahisa Numakura, Koji Murakami, Tsutomu Tamada, Chiaki Yamaguchi, Chihiro Inoue, Shinya Ohkouchi, Naoki Tode, Hirohito Sano, Hiroyuki Aizawa, Kei Sato, Ayumi Mitsune, Hajime Kurosawa, Toru Nakazawa, Hisatoshi Sugiura

Tohoku University

Research output: Contribution to journal › Review article › peer-review

4 Citations (Scopus)

Abstract

BNT162b2 (Pfizer/BioNTech) is a coronavirus disease 2019 (COVID-19) vaccine containing nucleoside-modified messenger RNA encoding the severe acute respiratory syndrome coronavirus 2 spike glycoprotein. Recently, ocular complications of mRNA vaccines have been reported increasingly frequently. However, immunological adverse events due to mRNA vaccines in real-world settings are not fully known. We herein report the novel development of sarcoidosis manifested as uveitis, bilateral hilar lymphadenopathy, angiotensin-converting enzyme elevation, and epithelioid and giant cell granuloma formation in the lung soon after the first BNT162b2 injection and review the current literature, including three reported cases of sarcoid-like reaction following COVID-19 vaccination.

Original language	English
Pages (from-to)	3101-3106
Number of pages	6
Journal	Internal Medicine
Volume	61
Issue number	20
DOIs	https://doi.org/10.2169/internalmedicine.0104-22
Publication status	Published - 2022

Keywords

COVID-19
angiotensin-converting enzyme (ACE)
mRNA vaccine
sarcoidosis
uveitis

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2169/internalmedicine.0104-22

Cite this

@article{16d009d53267471fadfd818383e5e8ba,

title = "A Novel Development of Sarcoidosis Following COVID-19 Vaccination and a Literature Review",

abstract = "BNT162b2 (Pfizer/BioNTech) is a coronavirus disease 2019 (COVID-19) vaccine containing nucleoside-modified messenger RNA encoding the severe acute respiratory syndrome coronavirus 2 spike glycoprotein. Recently, ocular complications of mRNA vaccines have been reported increasingly frequently. However, immunological adverse events due to mRNA vaccines in real-world settings are not fully known. We herein report the novel development of sarcoidosis manifested as uveitis, bilateral hilar lymphadenopathy, angiotensin-converting enzyme elevation, and epithelioid and giant cell granuloma formation in the lung soon after the first BNT162b2 injection and review the current literature, including three reported cases of sarcoid-like reaction following COVID-19 vaccination.",

keywords = "COVID-19, angiotensin-converting enzyme (ACE), mRNA vaccine, sarcoidosis, uveitis",

author = "Tadahisa Numakura and Koji Murakami and Tsutomu Tamada and Chiaki Yamaguchi and Chihiro Inoue and Shinya Ohkouchi and Naoki Tode and Hirohito Sano and Hiroyuki Aizawa and Kei Sato and Ayumi Mitsune and Hajime Kurosawa and Toru Nakazawa and Hisatoshi Sugiura",

note = "Funding Information: This work was supported in part by a Grant-in-Aid for Early-Career Scientists from the Ministry of Education, Sciences, Sports, and Technology (MEXT), Japan, to T. Numakura (21K 16106). Publisher Copyright: {\textcopyright} 2022 Japanese Society of Internal Medicine. All rights reserved.",

year = "2022",

doi = "10.2169/internalmedicine.0104-22",

language = "English",

volume = "61",

pages = "3101--3106",

journal = "Internal Medicine",

issn = "0918-2918",

publisher = "Japanese Society of Internal Medicine",

number = "20",

}

TY - JOUR

T1 - A Novel Development of Sarcoidosis Following COVID-19 Vaccination and a Literature Review

AU - Numakura, Tadahisa

AU - Murakami, Koji

AU - Tamada, Tsutomu

AU - Yamaguchi, Chiaki

AU - Inoue, Chihiro

AU - Ohkouchi, Shinya

AU - Tode, Naoki

AU - Sano, Hirohito

AU - Aizawa, Hiroyuki

AU - Sato, Kei

AU - Mitsune, Ayumi

AU - Kurosawa, Hajime

AU - Nakazawa, Toru

AU - Sugiura, Hisatoshi

N1 - Funding Information: This work was supported in part by a Grant-in-Aid for Early-Career Scientists from the Ministry of Education, Sciences, Sports, and Technology (MEXT), Japan, to T. Numakura (21K 16106). Publisher Copyright: © 2022 Japanese Society of Internal Medicine. All rights reserved.

PY - 2022

Y1 - 2022

N2 - BNT162b2 (Pfizer/BioNTech) is a coronavirus disease 2019 (COVID-19) vaccine containing nucleoside-modified messenger RNA encoding the severe acute respiratory syndrome coronavirus 2 spike glycoprotein. Recently, ocular complications of mRNA vaccines have been reported increasingly frequently. However, immunological adverse events due to mRNA vaccines in real-world settings are not fully known. We herein report the novel development of sarcoidosis manifested as uveitis, bilateral hilar lymphadenopathy, angiotensin-converting enzyme elevation, and epithelioid and giant cell granuloma formation in the lung soon after the first BNT162b2 injection and review the current literature, including three reported cases of sarcoid-like reaction following COVID-19 vaccination.

AB - BNT162b2 (Pfizer/BioNTech) is a coronavirus disease 2019 (COVID-19) vaccine containing nucleoside-modified messenger RNA encoding the severe acute respiratory syndrome coronavirus 2 spike glycoprotein. Recently, ocular complications of mRNA vaccines have been reported increasingly frequently. However, immunological adverse events due to mRNA vaccines in real-world settings are not fully known. We herein report the novel development of sarcoidosis manifested as uveitis, bilateral hilar lymphadenopathy, angiotensin-converting enzyme elevation, and epithelioid and giant cell granuloma formation in the lung soon after the first BNT162b2 injection and review the current literature, including three reported cases of sarcoid-like reaction following COVID-19 vaccination.

KW - COVID-19

KW - angiotensin-converting enzyme (ACE)

KW - mRNA vaccine

KW - sarcoidosis

KW - uveitis

UR - http://www.scopus.com/inward/record.url?scp=85140144763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85140144763&partnerID=8YFLogxK

U2 - 10.2169/internalmedicine.0104-22

DO - 10.2169/internalmedicine.0104-22

M3 - Review article

C2 - 35945009

AN - SCOPUS:85140144763

SN - 0918-2918

VL - 61

SP - 3101

EP - 3106

JO - Internal Medicine

JF - Internal Medicine

IS - 20

ER -

A Novel Development of Sarcoidosis Following COVID-19 Vaccination and a Literature Review

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Recent Findings from Tohoku University Provides New Insights into COVID-19 (A Novel Development of Sarcoidosis Following Covid-19 Vaccination and a Literature Review)

Cite this

A Novel Development of Sarcoidosis Following COVID-19 Vaccination and a Literature Review

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Press/Media

Recent Findings from Tohoku University Provides New Insights into COVID-19 (A Novel Development of Sarcoidosis Following Covid-19 Vaccination and a Literature Review)

Cite this